Improving breathing and exercise capacity in heart failure patients with obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how pulmonary limitations affect exertional dyspnea and exercise capacity in patients with heart failure with preserved ejection fraction (HFpEF) and obesity. It includes clinical screening tests such as cardiopulmonary exercise testing and pulmonary function testing to assess the interaction between HFpEF and obesity. The study will also conduct a randomized, placebo-controlled trial to evaluate the effects of breathing a helium-oxygen gas mixture on reducing obesity-related breathing constraints. The goal is to determine if this intervention can improve functional outcomes for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* signs and symptoms of heart failure
* an ejection fraction \> 0.50;
* objective evidence of diastolic dysfunction. elevated biomarkers (NT-proBNP \>300 ng/dl) or HF hospitalization
* healthy volunteers

Exclusion Criteria:

* age \< 55 years
* BMI \> 50 kg/m2
* Atrial fibrillation with poorly controlled heart rate
* phosphodiesterase type 5 (PDE5) inhibitor use
* severe valvular disease
* severe Chronic obstructive pulmonary disease (COPD)
* Chronic kidney disease (CKD) 4 or higher
* any restriction of ambulation and mobility.

Where it's running

• UT Southwestern Medical Center
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Tony G Babb, Ph.D. — University of Texas Southwestern Medical Center
• Study coordinator: Raksa B Moran, RN
• Email: raksamoran@texashealth.org
• Phone: 214-345-6574

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Incretin therapy with tirzepatide for obesity-related HFpEF

  A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.

  Recruiting Phase 4 Columbia University · New York, New York · NCT07554638

• Maridebart cafraglutide for people with obesity and preserved or mildly reduced ejection fraction heart failure

  This trial will test whether adding maridebart cafraglutide to usual heart-failure care can reduce hospital visits, cardiovascular deaths, and improve symptoms in adults with obesity and HFpEF or HFmrEF.

  Recruiting at 651 sites Phase 3 Amgen · Birmingham, Alabama and 685 other locations · NCT07037459

• Effects of weight loss on heart health in obese patients with heart failure

  This study tests if losing weight can help improve heart health in overweight or obese people with heart failure.

  Recruiting University of Oxford · Oxford · NCT05878912

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.